Tango Therapeutics, Inc. (TNGX)

Tango Therapeutics' stock has experienced significant movement over the past six months, with a 90.92% increase. As of February 2, 2026, the share price was $11.94, a 310.31% increase from February 3, 2025. Key events include a positive Q3 2025 earnings report, Q2 2025 revenues missing estimates, a $212.0 million equity raise, and positive early clinical data.

As a clinical-stage biotechnology company, Tango Therapeutics does not have commercialized products subject to typical demand seasonality. Demand for its product candidates is driven by clinical trial progress, regulatory approvals, and unmet medical needs.

Tango Therapeutics is a clinical-stage biotechnology company focused on discovering and delivering precision cancer medicines by leveraging the genetic principle of synthetic lethality. Its product candidates include TNG462, TNG456, TNG260, TNG908 and TNG348, which are in various stages of clinical development. The company also has strategic collaborations with GSK and Merck.

Tango Therapeutics is headquartered in Boston, Massachusetts, USA. Its operations are centered around research and development, with no extensive global footprint for product sales or commercial operations.

Tango Therapeutics holds a positive brand reputation within the biotechnology sector, with a consensus rating of "Strong Buy" or "Moderate Buy" from analysts. Strategic collaborations with GSK and Merck contribute positively to its reputation. No specific events negatively impacted its brand reputation in the past year beyond general industry risks.

Tango Therapeutics has a significant institutional ownership presence, with 249 institutional owners holding 148,202,206 shares as of February 2, 2026. Top holders include Trv Gp Iv, Llc, Farallon Capital Management Llc, and EcoR1 Capital, LLC. Barbara Weber and Adam Crystal are listed as insider owners.